Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups

di Gagez, A-L, Tuaillon, E, Cezar, R, Dartigeas, C, Mahé, B, Letestu, R, Maisonneuve, H, Gouilleux-Gruart, V, Bollore, K, Ferrant, E, Aurran, T, Feugier, P, Leprêtre, S, Cartron, G
Pubblicato in Blood Cancer J (2016)